Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations

Conditions:   NSCLC, Stage IV;   NSCLC Stage IIIB;   NSCLC, Stage IIIC;   NSCLC, Recurrent;   EGFR Exon 20 Insertion Mutation;   HER2-activating Mutation Intervention:   Drug: tarloxotinib bromide Sponsor:   Rain Therapeutics Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials